



Versameb to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting

- *Developing RNA molecules which target multiple proteins in a single construct into cancer therapeutics*

5 April 2022, Basel, Switzerland: Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces it will present a poster entitled ‘*Design of combinatory RNA molecules to simultaneously activate tumor immunity and target several signaling pathways in solid tumors*’ on the 11th of April at the [American Association of Cancer Research \(AACR\) Annual Meeting](#), taking place in New Orleans, USA on the 8 – 13 April 2022. [An e-poster will be made available online at 2 pm CDT, April 8, 2022].

The poster will present data on Versameb’s technology platform *VERSagile* which enables combinatorial approaches of nucleotide therapeutics that comprise an mRNA element covalently linked to up to three independent siRNA elements targeting various oncogenes. Such constructs allow a synchronized up- and down regulation of different proteins in parallel, which opens the opportunity to address up to four cancer targets within a single RNA molecule.

Versameb aims to develop mRNA combination constructs into cancer therapeutics that target several pro-tumorigenic pathways simultaneously with a single molecule overcoming hurdles of efficacy, resistance and tumor heterogeneity.

[American Association of Cancer Research \(AACR\) Annual Meeting](#)

Title: *Design of combinatory RNA molecules to simultaneously activate tumor immunity and target several signaling pathways in solid tumors*

Session name and category: *PO.ET01.05 - Drug Conjugates / Bispecific Antibodies*, New Orleans Convention Center, Section 22

Abstract: 4454

Authors: *Petra Hillmann, Justin A. Selvaraj, Sina E. Zimmerli, Pascale G. Birrer, Claudia C. Bohnert, Klaas P. Zuideveld, Stefan J. Scherer, Friedrich Metzger*

Date & Time: *Monday, 11 April 2022, 09.00am – 12.30pm CDT*

The abstract is available online via the AACR Annual Meeting website at

<https://www.abstractsonline.com/pp8/#!/10517/presentation/12265>

Klaas Zuideveld, Chief Executive Officer of Versameb, said: “We are excited to be presenting at the American Association of Cancer Research to highlight Versameb’s truly differentiated approach to creating novel anti-tumor therapeutics, which we are actively progressing towards the clinic while advancing our *VERSagile* platform.”

Friedrich Metzger, Chief Scientific Officer, said: “Our data validate that combinatory RNA constructs can be developed into cancer and other therapeutics to overcome the limitations of current approaches to treating severe and debilitating diseases.”

-Ends-



Contact for media enquiries:

Versameb

Klaas Zuideveld, CEO

ir@versameb.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Zoe Bolt

Tel: +44 (0)20 3882 9621

versameb@optimumcomms.com

About Versameb

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb's proprietary technology platform, *VERSagile*, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve.

The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards a first in-human/proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at www.versameb.com as well as on [LinkedIn](#).

About American Association for Cancer Research

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.